ADORA2A and hereditary clear cell renal cell carcinoma: In renal cell carcinoma, phase I results from the first clinical trial of A2AR antagonist exhibited durable clinical improvement with immune response restoration even in patients resistant or refractory to PD-1/PD-L1 inhibitors (56).